Effects of Mitophagy on Regulatory T Cell Function in Patients With Myasthenia Gravis

被引:15
|
作者
Wang, Na [1 ]
Yuan, Jiang [1 ]
Karim, Md Rezaul [1 ,2 ]
Zhong, Ping [3 ]
Sun, Yan-Peng [1 ]
Zhang, Hong-Yan [1 ]
Wang, Yun-Fu [1 ,2 ]
机构
[1] Hubei Univ Med, Dept Neurol, Taihe Hosp, Shiyan, Peoples R China
[2] Hubei Univ Med, Biomed Res Inst, Shiyan, Peoples R China
[3] Hubei Univ Med, Dept Prevent Med, Shiyan, Peoples R China
来源
FRONTIERS IN NEUROLOGY | 2020年 / 11卷
基金
中国国家自然科学基金;
关键词
myasthenia gravis; mitophagy; regulatory T cell; rapamycin; 3-methyladenine; IMMUNOSUPPRESSIVE THERAPY; AUTOPHAGY; MTOR; TREG; TACROLIMUS; SYSTEM; ROLES;
D O I
10.3389/fneur.2020.00238
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objective: This study was conducted to determine whether regulatory T cells (CD4(+)CD25(+)T, Tregs) show abnormal mitophagy as well as the function of Tregs in patients with myasthenia gravis (MG). Methods: CD4(+)T cells and CD4(+)CD25(+)Treg cells were obtained from 15 patients with MG (MG group) and 15 controls (N group). Tregs from the MG group were subjected to rapamycin-induced culture for 48 h (Rapa group) and 3-methyladenine-induced culture for 48 h (3-MA group). The levels of mitophagy in Tregs were then observed through electron and confocal microscopy. Expression of the autophagy-related protein LC3-II was detected by western blotting, and mitochondrial function in each group was evaluated by flow cytometry. Inhibition of Treg cell proliferation was detected by flow cytometry. Results: Mitophagy in the MG group was lower than that in the N group; it was higher in the Rapa group compared to that in the MG group and lowered in the 3-MA group than in the MG group. Expression of the autophagy-related protein LC3-II was lower in the MG group than in the N group, higher in the Rapa group than in the MG group, and lower in the 3-MA group than in the MG group. The mitochondrial membrane potential was lower in the MG group compared to that in the N group; it was higher in the Rapa group than in the MG group and lowered in the 3-MA group than in the MG group. Inhibition of Treg proliferation was lower in the MG group than in the N group; it was higher in the Rapa group than in the MG group and lowered in the 3-MA group than in the MG group. Conclusion: The decreased mitochondrial membrane potential and mitophagy in Tregs in the MG group may be related to a decreased inhibition of Treg proliferation. The mitochondrial membrane potential was increased after adding the autophagy agent Rapa to enhance mitophagy, and the proliferation inhibition function of Tregs was also enhanced. The autophagy agent 3-MA down-regulated mitophagy, which decreased the mitochondrial membrane potential and inhibitory effect of Tregs. These results reveal the possible cellular immune mechanism of Treg dysfunction in MG.
引用
收藏
页数:11
相关论文
共 50 条
  • [1] Rituximab in myasthenia gravis: a "to be or not to be" inhibitor of T cell function
    Marino, Mariapaola
    Bartoccioni, Emanuela
    Alboini, Paolo Emilio
    Evoli, Amelia
    ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, 2018, 1413 (01) : 41 - 48
  • [2] Circulating regulatory anti-T cell receptor antibodies in patients with myasthenia gravis
    Jambou, F
    Zhang, W
    Menestrier, M
    Klingel-Schmitt, I
    Michel, O
    Caillat-Zucman, S
    Aissaoui, A
    Landemarre, L
    Berrih-Aknin, S
    Cohen-Kaminsky, S
    JOURNAL OF CLINICAL INVESTIGATION, 2003, 112 (02): : 265 - 274
  • [3] Undiminished regulatory T cells in the thymus of patients with myasthenia gravis
    Matsui, N.
    Nakane, S.
    Saito, F.
    Ohigashi, I.
    Nakagawa, Y.
    Kurobe, H.
    Takizawa, H.
    Mitsui, T.
    Kondo, K.
    Kitagawa, T.
    Takahama, Y.
    Kaji, R.
    NEUROLOGY, 2010, 74 (10) : 816 - 820
  • [4] Circulating Regulatory T Cells in Patients with Autoimmune Myasthenia Gravis
    Meriggioli, Matthew N.
    Muthusamy, Thirupathy
    Sheng, Jian Rong
    Rowin, Julie
    Prabhakar, Bellur S.
    NEUROLOGY, 2011, 76 (09) : A644 - A644
  • [5] UNDIMINISHED REGULATORY T CELLS IN THE THYMUS OF PATIENTS WITH MYASTHENIA GRAVIS Reply
    Kaji, R.
    Matsui, N.
    Takahama, Y.
    Nakane, S.
    NEUROLOGY, 2010, 75 (12) : 1121 - 1121
  • [6] Regulatory T cell-based immunotherapies in experimental autoimmune myasthenia gravis
    Souroujon, Miriam C.
    Aricha, Revital
    Feferman, Tali
    Mizrachi, Keren
    Reuveni, Debby
    Fuchs, Sara
    MYASTHENIA GRAVIS AND RELATED DISORDERS I, 2012, 1274 : 120 - 126
  • [7] CD4+ FoxP3+ T regulatory cell subsets in myasthenia gravis patients
    Kohler, Siegfried
    Keil, Thomas Oskar Philipp
    Hoffmann, Sarah
    Swierzy, Marc
    Ismail, Mahmoud
    Rueckert, Jens Carsten
    Alexander, Tobias
    Meisel, Andreas
    CLINICAL IMMUNOLOGY, 2017, 179 : 40 - 46
  • [8] Effects of age on T cell tolerance to the autoantigen in myasthenia gravis
    Stacy, Sue
    Standifer, Nathan E.
    Krolick, Keith A.
    Infante, Anthony J.
    Kraig, Ellen
    JOURNAL OF IMMUNOLOGY, 2006, 176 : S281 - S281
  • [9] Regulatory T cells in multiple sclerosis and myasthenia gravis
    K. M. Danikowski
    S. Jayaraman
    B. S. Prabhakar
    Journal of Neuroinflammation, 14
  • [10] Dysfunctional Regulatory T Cells in Patients with Autoimmune Myasthenia Gravis: Therapeutic Targets?
    Meriggioli, Matthew
    Muthusamy, Thirupathy
    Rowin, Julie
    Sheng, Jian Rong
    Prabhakar, Bellur
    NEUROLOGY, 2012, 78